LEAP THERAPEUTICS
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
LEAP THERAPEUTICS
Industry:
Biotechnology Life Science
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.leaptx.com
Total Employee:
11+
Status:
Active
Contact:
(617)714-0360
Email Addresses:
[email protected]
Total Funding:
226.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Actimed Therapeutics
Actimed Therapeutics is a UK clinical stage biopharmaceutical company
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Cassava Sciences
Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience.
Chromis Therapeutics
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company
Cloudbreak Therapeutics
Cloudbreak Therapeutics is a clinical stage biotechnology company
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Cycle Pharmaceuticals
Cycle Pharmaceuticals is a pioneering pharmaceutical company.
Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies.
Eirion Therapeutics
Eirion Therapeutics is a clinical-stage biopharmaceutical company that is developing next-generation prescription products.
Exvastat
Exvastat is an innovative, preclinical-stage pharmaceutical company.
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Halia Therapeutics
Halia is a preclinical-stage biopharmaceutical company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Nano Cures
Nano Cures is clinical-stage biotechnology and infectious disease immunity platform company.
Osmotica Pharmaceutical
Osmotica Pharmaceutical is a global specialty pharmaceutical company.
Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals is a clinical stage biotech company.
Promontory Therapeutics
Promontory Therapeutics is a clinical-stage pharmaceutical company focused on novel therapeutics in oncology.
Aralez Pharmaceuticals
Aralez Pharmaceuticals is a global specialty pharmaceutical company.
Novelion Therapeutics
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company
Quell Therapeutics
Quell Therapeutics is a cell therapy company
Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical stage biotechnology company.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Saol Therapeutics
Saol Therapeutics is a biotech pharmaceutical company.
Sapient
Sapient is a full-service bioanalytical research organization.
Seaweed Solutions
Seaweed Solutions is a seaweed cultivator, innovator, and business development company.
SELLAS Life Sciences
SELLAS Life Sciences is a late-stage biopharmaceutical company.
Soleno Therapeutics
Soleno Therapeutics is a clinical-stage biopharmaceutical company.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company.
UroGen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company.
VivaVision Biotech
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company.
Vyriad
Vyriad is a clinical stage biopharmaceutical company.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-08-29 | MacroCure | MacroCure acquired by Leap Therapeutics | N/A |
Investors List
BeiGene
BeiGene investment in Post-IPO Equity - Leap Therapeutics
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Equity - Leap Therapeutics
Eli Lilly & Company Foundation
Eli Lilly & Company Foundation investment in Post-IPO Equity - Leap Therapeutics
HealthCare Ventures
HealthCare Ventures investment in Venture Round - Leap Therapeutics
Torrey Pines Investment
Torrey Pines Investment investment in Seed Round - Leap Therapeutics
Official Site Inspections
http://www.leaptx.com Semrush global rank: 4.61 M Semrush visits lastest month: 2.19 K
- Host name: vps22613.dreamhostps.com
- IP address: 69.163.201.207
- Location: Brea United States
- Latitude: 33.9339
- Longitude: -117.8854
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 92821
More informations about "Leap Therapeutics" on Search Engine
Leap Therapeutics, Inc.
May 13, 2015 Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.See details»
Leap Therapeutics - Crunchbase Company Profile & Funding
Leap Therapeutics is a clinical-stage biopharmaceutical company for development of targeted and immuno-oncology therapeutics. Cambridge, Massachusetts, United States. 11-50. Post-IPO Equity. Public. www.leaptx.com. 21,509. Highlights. Stock Symbol NASDAQ:LPTX. Acquisitions 2. Total Funding Amount. Unlock for free. Contacts 46. …See details»
Investors | Leap Therapeutics, Inc.
Mar 18, 2024 Corporate Profile. Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 …See details»
Leap Therapeutics | LinkedIn
Leap Therapeutics. 4,504 followers. 1w. We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop...See details»
Leap Therapeutics Announces Completion of Enrollment in …
Jan 2, 2024 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the...See details»
News Releases | Leap Therapeutics, Inc.
Jan 2, 2024 Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Jan 16, 2024 Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumSee details»
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 …
Dec 31, 2022 CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022. Leap Highlights:See details»
Science - Leap Therapeutics, Inc.
Leap Therapeutics is developing targeted therapies for cancer patients with DKK1expressing tumors.See details»
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 …
CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...See details»
About - Leap Therapeutics, Inc.
About. Leap Therapeutics. is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.See details»
Leap Therapeutics Announces $40 Million Private Placement
Apr 11, 2024 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase...See details»
Leap Therapeutics - Funding, Financials, Valuation & Investors
$226.5M. in funding over 9 rounds. Their latest funding was raised on Sep 22, 2021 from a Post-IPO Equity round. Leap Therapeutics is registered under the ticker NASDAQ:LPTX . Leap Therapeutics is funded by 5 investors. BeiGene and Lincoln Park Capital Fund are the most recent investors. Leap Therapeutics has acquired 2 organizations.See details»
Leap Therapeutics Reports Third Quarter 2023 Financial Results
Nov 13, 2023 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended...See details»
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 …
CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...See details»
Leap Therapeutics Announces Completion of Enrollment in …
Jan 2, 2024 PDF Version. CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN …See details»
Patients - Leap Therapeutics, Inc.
We work every day to develop new targeted therapies for cancer patients. Click below to learn more about our clinical trials and for links to resources for patients. Leap Therapeutics’ DKN-01 is being tested in gastric cancer; prostate cancer, endometrial cancer, colorectal cancer, and lung cancer.See details»
Leap Therapeutics to Present New Clinical Data from Part A of …
CAMBRIDGE, Mass., Jan. 16, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced new data from Part A of the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 ( DKK1) antibody, in …See details»
Flame Biosciences acquired by Leap Therapeutics - Crunchbase
Jan 17, 2023 Summary. Overview. Acquired Organization: Flame Biosciences Flame Biosciences is a clinical-stage company focused on therapies for cancer and other inflammatory diseases. Acquiring Organization: Leap Therapeutics Leap Therapeutics is a clinical-stage biopharmaceutical company for development of targeted and immuno …See details»
Leap Therapeutics Acquires Flame Biosciences
Dec 31, 2022 Leap Therapeutics Acquires Flame Biosciences. January 17, 2023. LPTX - Flame Acquisition Final. Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline. Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL …See details»
Careers - Leap Therapeutics, Inc.
Join us at Leap Therapeutics, a patient-focused company developing targeted and immuno-oncology therapeutics. Explore how you can join us in making a direct positive impact in the lives of individuals with cancer. We are …See details»